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Objectives​: In severe heart disease, parenteral administration of loop diuretic is often 
needed. We present clinical outcomes from episodes of care using subcutaneous continuous 
infusion of furosemide (CSCI-furosemide). 
 
Methods​: Retrospective review of service improvement data. The heart failure nurse 
specialist, supported by the heart failure-palliative care multi-disciplinary team, works with 
the community or hospice staff who administer the CSCI-furosemide. Data collected for 
consecutive patients receiving CSCI-furosemide included: age, sex, New York Heart 
Association (NYHA) class, preferred place of care, goal of treatment, infusion-site reactions, 
and signs and symptoms of fluid retention (including weight and self-reported 
breathlessness). 
 
Results​: 116 people (men 86 [66%]; mean age 79 years, 49 to 97; NYHA class 3 [36/116, 
31%] or 4 heart failure [80/116, 69%]) received 130 episodes of CSCI-furosemide (average 
duration 10 days, 1 to 49), over half in the patient’s own home/care home (80/129,; 61%) 
aiming to prevent hospital admission. 40/129 (31%) were managed in the hospice, and 9 
(7.0%) in a community hospital. Average daily furosemide dose was 125 mg (40 to 300mg). 
The goal of treatment was achieved in (119/130, 91.5%) episodes. 
 
The median reduction in weight was 4kg (interquartiles -7 kg to -2 kgs, -22 to +9 kgs). 
Self-reported breathlessness reduced from 8.2 (+/-1.9) to 5.2 (+/-1.8).  ​Adverse events 
occurred in 31/130 (24%) episodes; all but 4/130 (3%, localised skin infection) were mild. 
 
Conclusions​: These preliminary data indicate that CSCI-furosemide is safe and effective for 










Despite effective heart failure treatments and a reduced 10-year mortality ​(1)​, progression to 
advanced disease remains a cause of poor quality of life.​(2)​ Congestive symptoms are a 
hallmark of heart failure, often needing parenteral loop diuretic, usually intravenous (IV) as 
a hospital in-patient.​(3) ​In advanced disease, the focus shifts to symptom control and quality 
of life. For many, this means care at home where possible. Hospital admission drives the 
considerable health service costs,​(4)​ and which​ ​for older people with chronic health 
conditions may also worsen frailty, sarcopenia, and cause nosocomial infections, 
contributing to functional decline.​ (5,6)​ This potential vicious cycle jeopardises independent 
living, and may mean death in hospital by default.  
 
Community administered parenteral diuretics, either IV where community services exist, or 
subcutaneous is a possible solution.​(7)​ A British Heart Foundation (BHF) pilot of community 
IV furosemide (n=126) found preliminary evidence of safety, benefit and 
cost-effectiveness.​(8)​ A retrospective case-review of 43 episodes of continuous subcutaneous 
infusion of furosemide (CSCI-furosemide)​ ​in 32 people with advanced heart failure showed 
promising weight loss, and support for patient-preferred place of care.​(9)​ The NICE chronic 
heart failure guideline,​(3)​ highlighted subcutaneous diuretic administration as a research 
priority area. Since then, a nearly 100% bioavailability of subcutaneous furosemide has been 
demonstrated ​[10]​ and a pilot randomised controlled trial of subcutaneous versus IV has 
shown equivalent weight loss and diuresis.​(10)​  As there are still relatively few data to inform 
clinical practice, we continued our CSCI-furosemide service improvement routine data 
collection,​(9)​ and report findings from this larger cohort regarding fluid balance and 
management goals.  
 
METHODS 
This retrospective review of anonymised service improvement initiative data is reported 
according to SQUIRE.​(11)​ Ethics approval was not required. Institutional approval was 
obtained.  
Consecutive patients from a regional heart failure-palliative care multi-disciplinary service 
(heart failure nurses, palliative physician, cardiologists) were eligible for CSCI-furosemide if 
they; i) had optimised heart failure management, ii) required parenteral diuretic, iii) had a 
preferred place of care as home, hospice or care home, iv) had sufficient community 
support (informal and clinical).  Patients received CSCI-furosemide according to 
institutionally-approved guidance, had contemporaneous data collected routinely using an 
anonymised proforma. No formal service improvement framework was used, but national 
heart failure treatment guidance was followed.​(3) 
 
The service is delivered by the heart failure nurse specialist working with general 
practitioners and community nurses, who administer the CSCI-furosemide; all having access 
to cardiologist advice. Furosemide for IV injection was used, diluted if needed with 0.9% 
saline, and infused over 24 hours using a subcutaneous syringe driver. The starting dose was 
estimated as the previous 24 hour oral dose: e.g. if the patient was taking 120mg/24 hours 




Data were collected by the usual care clinician and combined for Cohort A (October 2006 to 
July 2009, previously published, fluid overload symptoms and signs not collected),​(9) ​and 
Cohort B (until July 2019, symptoms and signs collected). The service continued to gain a 
larger sample size, and record impact on signs and symptoms.  
Clinical-demographic characteristics were recorded (age, sex, New York Heart Association 
(NYHA) class, place of care, preferred place of care, signs and symptoms [cohort B]) and 
treatment characteristics (dose, number of treatment days, adverse effects). Goals of care 
were noted: i) at home/care home wishing to prevent hospital admission; ii) in hospital, aim 
to facilitate discharge despite continued need for parenteral diuretics, iii) in hospice, aiming 
to stabilise heart failure, iv) in hospice, aiming to prevent terminal pulmonary oedema. Signs 
of fluid retention included jugular venous pressure (JVP) height, pulse, blood pressure, chest 
crackles and peripheral oedema were categorised as: i) JVP - not visible, <3 cm, >3 cm; ii) 
chest crackles - clear, basal, whole chest; iii) oedema -none, mild (below knee), moderate 
(above knee), severe (truncal/ascites). Patient-reported breathlessness used a 0 to 10 rating 
scale of “breathlessness now” (0 = no breathlessness; 10 = worst imaginable 
breathlessness). Site reactions categories were; infection (antibiotics prescribed, cellulitis), 
mild (erythema, bleeding, sore, swelling, trauma), practical (dislodged, leaking), or not 
described.  We assumed clinical entry more likely for adverse events, with details if serious, 
so: i) where “No” was ticked, but there ​was​ descriptive text, we counted as ”Yes” and 
categorised according to the description; ii)  missing responses were counted as “No”; iii) 
where “Yes” was ticked but with no details, we assumed a mild reaction.  
Descriptive statistics are tabulated. In this clinical dataset, there are missing data; the 
denominator represents the number of episodes for which the item was recorded. 
Assumptions were made for i) adverse events as above; ii) oedema - the most severe 
response was counted, iii) place and goal of care discrepancies agreed (MJ, EB) (e.g. place = 
“home”, goal = “in hospital, aim of home discharge”; counted as “hospital”).  With mutually 
exclusive options, data were treated as missing.  
 
RESULTS 
116 people with chronic advanced heart failure (men 86 [66.2%], mean age 79 years; 
standard deviation [SD] 10; range 49 to 97, NYHA class 3 [36/116, 31%] or 4 [80/116, 69%]) 
received 130 episodes of CSCI-furosemide (cohort A = 43, cohort B = 87) (see Online Table 1 
for details).  
 
Most episodes occurred in the patient’s home or care home (80/129; 61%). A further 
40/129 (31%) were in the hospice, and 9 (7%) in a community hospital.  
 
The median duration was 10 days (interquartile range [IQR] 6 to 14, range 1 to 49). Mean 
daily starting dose was 125 mg and 137 mg at the end (range 40 to 300mg). The injection 
site was changed on average once ​per​ episode. 
 




Signs of fluid overload (Table 1) showed: JVP > 3 cms in two-thirds, most had additional 
chest sounds, and over half had severe peripheral oedema. Self-reported breathlessness at 
baseline was severe (mean 8.2; SD 1.9).  
 
End-of-episode data entry for signs and symptoms was less complete; some clinicians felt 
the measures were too burdensome, or they had insufficient time. However, anecdotal 
comment was that CSCI-furosemide was helpful. Median weight reduction was ─4kg 
(IQR─7 kg to ─2 kgs, range ─22 to +9 kgs); 8/36 (22%) had a JVP > 3cm; 18/41 (44%) had 
chest crackles/wheeze and 4/50 (8%) had severe peripheral oedema. Self-reported 
breathlessness reduced (mean 5.2; SD 1.8). Pulse and blood pressure were stable.  
 
Adverse events in 31/130 (24%) episodes were mostly mild (25/130; 19%) or practical 
problems (6/130; 5%). A few, 4/130 (3%), had localised site infections. 
 
Table 1. Measures at baseline and end of episode 
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Yes  119 (91.5%)  
No  11 (8.5%)  
Total (n)  130  
Signs and Symptoms 
JVP 
1= not visible 12 (18.5%) 13 (36.1%)  
2= <3cm 10 (15.4%) 15 (41.7%)  
3= >3cm 43 (66.2%) 8 (22.2%)  
Total (n) 65 36  
Pulse ​(beats per minute) 
(mean; SD) 




Systolic BP ​(mmHg) 
(mean; SD) 
111.0 +/- 33.0 112.0 +/- 30.0 1.0 +/- 44.6 
 
Diastolic BP ​(mmHg) 
(mean; SD) 
64.0 +/- 15.0 62.0 +/- 13.0 2.0 +/- 19.8 
 
Weight ​(kg) 
(median; lower quartile to 
upper quartile; range) 
81; 73 to 103; 45 
to 152 
 
77; 69 to 100; 38 to 
130 
̶ 4;  ̶ 7 to  ̶ 2;  
̶ 22 to + 9 
 
Oedema 
1= none 0 (0.0%) 14(28%)  
2= mild - below knee 9 (12.5%) 24 (48%)  
3= moderate - above knee 19 (26.4%) 8 (16.0%)  
4= severe - truncal/ascites 47 (66.6%) 4 (8.0%)  
Total (n)  75  50  
Crackles 
1= clear 9 (12.5%) 24 (58.5%)  
2= crackles/wheeze base 
only 
39 (54.2%) 16 (39.0%)  
*erythema 11 (8.5%); bleeding 1 (1.5%); swelling 1 (0.8%); trauma 1 (0.8%) 
** dislodged 5 (3.8%); leaking 1 (0.8%) 





We build on previous data​(9) ​demonstrating effective, safe use of CSCI-furosemide, delivered 
within current resources (staff, equipment, medication).  Clinically important weight loss, 
improved signs and symptoms, and support for preferred place of care was achieved. Nearly 
a quarter had site reactions but most were mild.  
 
Our findings compare well with the BHF pilot study​(8)​  which recorded a median 2.2kg (0.2 – 
15.4kg) loss over a similar duration; average 7 days, range 1 to 32 days. Just under 
two-thirds of the IV interventions were clinically effective. The BHF pilot had more people 
with NYHA III (55% [BHF] vs 29% [our data]).  People with NYHA IV disease and agreed 
ceilings of treatment (standard in our service) may have higher hospital transfer thresholds. 
This may explain the 20% hospital admissions in the BHF pilot. Our findings are consistent 
with a previous report (n =36)​(12)​ with average 4Kg weight loss respectively (average 11 days’ 
CSCI-furosemide). 
 
A ​proprietary buffered formulation (pH of 7.4) has been developed to minimize tissue 
irritation. The following studies all used this buffered solution. Two studies​(10)​ showed 
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3= crackles/wheeze whole 
chest 
24 (33.3%) 1 (2.4%)  
Total (n) 72 41  
Patient rating 
breathlessness​ (mean; sd; 
range) 
8.2 +/- 1.9; 0 to 
10 
5.2 +/- 1.8; 0 to 10 
 
-3.0 +/-2.6; − 
8 to 2 
Intervention 
Dose of  furosemide​ (mg) 
(mean; sd; range) 
124.8 +/- 49.6 
40-250 
136.6 +/- 48.8 
40-300 
 
Days of subcutaneous furosemide 
 Median; lower quartile to 
upper quartile; range 
 10; 6 to 14;  
1 to 49 
 
Site changed  
(median; lower quartile to 
upper quartile; range) 
 1; 0 to 2; 0 to 10 
 
 
Adverse events (n = 130) 
Total site reactions  31 (23.8%)  
Infection  4 (3.1%)  
Self-limiting mild reactions*  18 (13.8%)  
Practical problems**  6 (4.6%)  
Documented but not 
described*** 
 7 (5.4%)  
Total (n)  130  
almost 100% subcutaneous bioavailability: i) a proof-of-concept study and ii) a pivotal 
pharmacokinetic/pharmacodynamics study. None reported skin problems in the 
proof-of-concept study. In the pivotal study mild erythema (9/16) and skin irritation (6/16) 
was reported.​(10)​ Another pilot study reported no skin irritation.​(13)​ Two further pilot studies 
(conference abstracts only​(14)​) using longer administration reported reactions: i) 8 device 
problems and site discomfort in three participants over 48 hours; ii) 10 outpatients had​ 21 
device/delivery issues and 18 adverse events (mostly mild site discomfort) over 7 days. 
Buffered solution studies included far fewer NYHA III/IV patients and infusion duration was 
much shorter, nevertheless, our data are comparable.  
 
Strengths and limitations 
This study represents “real-life” practice by several clinicians, over time (years) despite staff 
changes. Cohort B data included signs and symptoms not routinely documented in 
community/hospice settings. 
There is no control group, and there are missing data. Our assumptions about reporting 
might be untrue. Calibrated weighing scales were not used, or standard procedures; 
self-weighing patients did so each morning, but times varied for others. Missing 
end-of-episode measurements may under-estimate deterioration, but clinicians anecdotally 
reported success. The NHS Trust is continuing the service, and other NHS Trusts have 
adopted/adapted our clinical guidelines. 
 
Implications for clinical practice and research 
Our benefit-safety profile is similar to the BHF IV pilot, and the early trials of the buffered 
solution. However, CSCI-furosemide uses clinical resources available UK-wide. A recent 
systematic review hails CSCI-furosemide as an important emerging intervention which, if 
confirmed in evaluative randomised controlled trials, would result in a “paradigm shift” in 






These preliminary data indicate that CSCI-furosemide for people with advanced heart failure 
who wish to avoid hospital admission is safe and effective. The findings should be confirmed 
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